TY - STD TI - Thorlund K, Dron L, Park J, Hsu G, Forrest JI, Mills EJ. A real-time dashboard of clinical trials for COVID-19. Lancet. 2020;2(6):E286–7. ID - ref1 ER - TY - STD TI - Cytel. Global coronavirus COVID-19 clinical trial tracker. Accessed 8 July 2020. ID - ref2 ER - TY - STD TI - COMET Initiative. “Meta-COS” for research in COVID-19 hospitalised patients. http://www.comet-initiative.org/assets/downloads/COVID-19%20meta%20COS_Table%201.pdf. Accessed23 Apr 2020. UR - http://www.comet-initiative.org/assets/downloads/COVID-19%20meta%20COS_Table%201.pdf; ID - ref3 ER - TY - STD TI - Initiative C. Core outcome set developers’ response to COVID-19 (15th April 2020). http://www.comet-initiative.org/Studies/Details/1538. Accessed 23 Apr 2020. UR - http://www.comet-initiative.org/Studies/Details/1538; ID - ref4 ER - TY - STD TI - Jin X, Pang B, Zhang J, Liu Q, Yang Z, Feng J, et al. Core outcome set for clinical trials on coronavirus disease 2019 (COS-COVID). Engineering (Beijing). 2020. Epub ahead of print. ID - ref5 ER - TY - STD TI - Qiu R, Wei X, Zhao M, Zhong C, Zhao C, Hu J, et al. Outcome reporting from protocols of clinical trials of coronavirus disease 2019 (COVID-19): a review. medRxiv. 2020. ID - ref6 ER - TY - STD TI - Qiu R, Zhao C, Liang T, Hao X, Huang Y, Zhang X, Chen Z, Wei X, Zhao M, Zhong C, Hu J, Li M, Han S, He T, Sun Y, Chen J, Shang H. Core Outcome Set for Clinical Trials of COVID-19 Based on Traditional Chinese and Western Medicine. Frontiers in pharmacology. 2020;11:781. https://doi.org/10.3389/fphar.2020.00781. ID - ref7 ER - TY - STD TI - ICH E9 working group. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf. Accessed 23 Apr 2020. UR - https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf; ID - ref8 ER - TY - JOUR AU - Akacha, M. AU - Bretz, F. AU - Ruberg, S. PY - 2017 DA - 2017// TI - Estimands in clinical trials - broadening the perspective JO - Stat Med VL - 36 UR - https://doi.org/10.1002/sim.7033 DO - 10.1002/sim.7033 ID - Akacha2017 ER - TY - JOUR AU - Akacha, M. AU - Kothny, W. PY - 2017 DA - 2017// TI - Estimands: a more strategic approach to study design and analysis JO - Clin Pharmacol Ther VL - 102 UR - https://doi.org/10.1002/cpt.872 DO - 10.1002/cpt.872 ID - Akacha2017 ER - TY - JOUR AU - Holzhauer, B. AU - Akacha, M. AU - Bermann, G. PY - 2015 DA - 2015// TI - Choice of estimand and analysis methods in diabetes trials with rescue medication JO - Pharm Stat VL - 14 UR - https://doi.org/10.1002/pst.1705 DO - 10.1002/pst.1705 ID - Holzhauer2015 ER - TY - JOUR AU - Leuchs, A. K. AU - Brandt, A. AU - Zinserling, J. AU - Benda, N. PY - 2017 DA - 2017// TI - Disentangling estimands and the intention-to-treat principle JO - Pharm Stat VL - 16 UR - https://doi.org/10.1002/pst.1791 DO - 10.1002/pst.1791 ID - Leuchs2017 ER - TY - JOUR AU - Mallinckrodt, C. AU - Molenberghs, G. AU - Rathmann, S. PY - 2017 DA - 2017// TI - Choosing estimands in clinical trials with missing data JO - Pharm Stat VL - 16 UR - https://doi.org/10.1002/pst.1765 DO - 10.1002/pst.1765 ID - Mallinckrodt2017 ER - TY - JOUR AU - Mallinckrodt, C. H. AU - Bell, J. AU - Liu, G. AU - Ratitch, B. AU - O’Kelly, M. AU - Lipkovich, I. PY - 2020 DA - 2020// TI - Aligning estimators with estimands in clinical trials: putting the ICH E9(R1) guidelines into practice JO - Ther Innov Regul Sci VL - 54 UR - https://doi.org/10.1007/s43441-019-00063-9 DO - 10.1007/s43441-019-00063-9 ID - Mallinckrodt2020 ER - TY - JOUR AU - Min, T. AU - Bain, S. C. PY - 2020 DA - 2020// TI - Estimands in diabetes clinical trials JO - Lancet Diabetes Endocrinol VL - 8 UR - https://doi.org/10.1016/S2213-8587(19)30407-3 DO - 10.1016/S2213-8587(19)30407-3 ID - Min2020 ER - TY - STD TI - Petavy F, Guizzaro L, Antunes Dos Reis I, Teerenstra S, KCB R. Beyond “intent-to-treat” and “per protocol”: improving assessment of treatment effects in clinical trials through the specification of an estimand. Br J Clin Pharmacol. 2019;86(7):1235–39. ID - ref16 ER - TY - JOUR AU - Ratitch, B. AU - Goel, N. AU - Mallinckrodt, C. AU - Bell, J. AU - Bartlett, J. W. AU - Molenberghs, G. PY - 2020 DA - 2020// TI - Defining efficacy estimands in clinical trials: examples illustrating ICH E9(R1) guidelines JO - Ther Innov Regul Sci. VL - 54 UR - https://doi.org/10.1007/s43441-019-00065-7 DO - 10.1007/s43441-019-00065-7 ID - Ratitch2020 ER - TY - JOUR AU - Rufibach, K. PY - 2019 DA - 2019// TI - Treatment effect quantification for time-to-event endpoints-estimands, analysis strategies, and beyond JO - Pharm Stat VL - 18 UR - https://doi.org/10.1002/pst.1917 DO - 10.1002/pst.1917 ID - Rufibach2019 ER - TY - STD TI - Benkeser D, Diaz I, Luedtke A, Segal J, Scharfstein D, Rosenblum M. Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for ordinal or time to event outcomes. medRxiv. 2020. ID - ref19 ER - TY - JOUR AU - Harhay, M. O. AU - Ratcliffe, S. J. AU - Small, D. S. AU - Suttner, L. H. AU - Crowther, M. J. AU - Halpern, S. D. PY - 2019 DA - 2019// TI - Measuring and analyzing length of stay in critical care trials JO - Med Care VL - 57 UR - https://doi.org/10.1097/MLR.0000000000001059 DO - 10.1097/MLR.0000000000001059 ID - Harhay2019 ER - TY - STD TI - Meyer RD, Ratitch B, Wolbers M, Marchenko O, Quan H, Li D, et al. Statistical issues and recommendations for clinical trials conducted during the COVID-19 pandemic. Stat Biopharm Res. 2020:1–13. https://doi.org/10.1080/19466315.2020.1779122. ID - ref21 ER - TY - STD TI - Degtyarev E, Rufibach K, Shentu Y, Yung G, Casey M, Englert S, et al. Assessing the impact of COVID-19 on the objective and analysis of oncology clinical trials – application of the estimand framework. Stat Biopharm Res. 2020:1–18. https://doi.org/10.1080/19466315.2020.1785543. ID - ref22 ER - TY - JOUR AU - Aroda, V. R. AU - Saugstrup, T. AU - Buse, J. B. AU - Donsmark, M. AU - Zacho, J. AU - Davies, M. J. PY - 2019 DA - 2019// TI - Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: the PIONEER 1 randomized clinical trial as an example JO - Diabetes Obes Metab VL - 21 UR - https://doi.org/10.1111/dom.13804 DO - 10.1111/dom.13804 ID - Aroda2019 ER - TY - STD TI - Statistical reviews for clinical trials testing treatments for COVID-19. https://zenodo.org/communities/covid-19-tx-rct-stats-review/?page=1&size=20. Accessed 27 Apr 2020. UR - https://zenodo.org/communities/covid-19-tx-rct-stats-review/?page=1&size=20 ID - ref24 ER - TY - STD TI - Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799. ID - ref25 ER - TY - JOUR AU - Colantuoni, E. AU - Scharfstein, D. O. AU - Wang, C. AU - Hashem, M. D. AU - Leroux, A. AU - Needham, D. M. PY - 2018 DA - 2018// TI - Statistical methods to compare functional outcomes in randomized controlled trials with high mortality JO - BMJ. VL - 360 UR - https://doi.org/10.1136/bmj.j5748 DO - 10.1136/bmj.j5748 ID - Colantuoni2018 ER - TY - JOUR AU - White, I. R. AU - Horton, N. J. AU - Carpenter, J. AU - Pocock, S. J. PY - 2011 DA - 2011// TI - Strategy for intention to treat analysis in randomised trials with missing outcome data JO - BMJ. VL - 342 UR - https://doi.org/10.1136/bmj.d40 DO - 10.1136/bmj.d40 ID - White2011 ER - TY - JOUR AU - Schulz, K. F. AU - Altman, D. G. AU - Moher, D. PY - 2010 DA - 2010// TI - CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials JO - PLoS Med VL - 7 UR - https://doi.org/10.1371/journal.pmed.1000251 DO - 10.1371/journal.pmed.1000251 ID - Schulz2010 ER - TY - JOUR AU - Dufouil, C. AU - Brayne, C. AU - Clayton, D. PY - 2004 DA - 2004// TI - Analysis of longitudinal studies with death and drop-out: a case study JO - Stat Med VL - 23 UR - https://doi.org/10.1002/sim.1821 DO - 10.1002/sim.1821 ID - Dufouil2004 ER - TY - JOUR AU - Finkelstein, D. M. AU - Schoenfeld, D. A. PY - 1999 DA - 1999// TI - Combining mortality and longitudinal measures in clinical trials JO - Stat Med VL - 18 UR - https://doi.org/3.0.CO;2-7 DO - 3.0.CO;2-7 ID - Finkelstein1999 ER - TY - JOUR AU - Pocock, S. J. AU - Ariti, C. A. AU - Collier, T. J. AU - Wang, D. PY - 2012 DA - 2012// TI - The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities JO - Eur Heart J VL - 33 UR - https://doi.org/10.1093/eurheartj/ehr352 DO - 10.1093/eurheartj/ehr352 ID - Pocock2012 ER - TY - STD TI - Clinicaltrials.gov. Trial of treatments for COVID-19 in hospitalized adults (DisCoVeRy). https://clinicaltrials.gov/ct2/show/NCT04315948. Accessed 27 Apr 2020. UR - https://clinicaltrials.gov/ct2/show/NCT04315948; ID - ref32 ER - TY - STD TI - Clinicaltrials.gov. Sarilumab COVID-19. https://clinicaltrials.gov/ct2/show/NCT04327388. Accessed 27 Apr 2020. UR - https://clinicaltrials.gov/ct2/show/NCT04327388; ID - ref33 ER - TY - STD TI - Clinicaltrials.gov. A randomized controlled clinical trial: hydroxychloroquine for the treatment of COVID-19 in hospitalized patients (OAHU-COVID19). https://www.clinicaltrials.gov/ct2/show/NCT04345692. Accessed 27 Apr 2020. UR - https://www.clinicaltrials.gov/ct2/show/NCT04345692; ID - ref34 ER - TY - STD TI - Organisation WH. WHO R&D Blueprint: COVID-19. Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis. https://www.who.int/blueprint/priority-diseases/key-action/informal-consultation-therapeutics-covid19-prophylaxis.pdf?ua=1. Accessed 27 Apr 2020. UR - https://www.who.int/blueprint/priority-diseases/key-action/informal-consultation-therapeutics-covid19-prophylaxis.pdf?ua=1; ID - ref35 ER - TY - JOUR AU - Cro, S. AU - Forbes, G. AU - Johnson, N. A. AU - Kahan, B. C. PY - 2020 DA - 2020// TI - Evidence of unexplained discrepancies between planned and conducted statistical analyses: a review of randomised trials JO - BMC Med VL - 18 UR - https://doi.org/10.1186/s12916-020-01590-1 DO - 10.1186/s12916-020-01590-1 ID - Cro2020 ER -